# Chromium

> Chromium is an essential trace mineral that supports insulin response and carbohydrate processing. Reactive hypoglycemia is common in the EDS/POTS/MCAS triad and produces palpitations, brain fog, fatigue, and shakiness that mimic POTS flares and trigger mast cell activity. ZebraThrive uses 200 mcg of chromium picolinate in the AM stack, the standard supplement dose with the deepest safety data.

**Page:** https://www.wellnessforzebras.com/ingredients/chromium
**Brand:** ZebraThrive
**Author:** Ken Chapman, Founder of ZebraThrive
**Last reviewed:** 2026-05-11
**Daily dose:** 200 mcg AM (chromium picolinate)
**Form used:** Chromium picolinate, USP grade, 200 mcg AM
**Target population:** Adults 18+ with hypermobile Ehlers-Danlos Syndrome (hEDS), Postural Orthostatic Tachycardia Syndrome (POTS), or Mast Cell Activation Syndrome (MCAS).
**Regulatory framing:** US DSHEA dietary supplement. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

## Key benefits

- Supports insulin response and post-meal glucose handling at the well-studied 200 mcg supplement dose
- Reactive hypoglycemia is common in the triad and produces palpitations, brain fog, fatigue, and shakiness that mimic POTS flares
- Picolinate chelate delivers 2-3% bioavailability (the highest of any practical chromium form)
- Foundational trace mineral with the deepest human safety record (200 mcg is the standard supplement dose)

## What it is

Chromium is an essential trace mineral that supports how your body responds to insulin and processes carbohydrates.

## Why we include it

We include it at 200 micrograms - the standard supplement dose with the deepest human safety data - because the EDS/POTS/MCAS triad commonly comes with overlapping reactive hypoglycemia. Post-meal blood sugar dips can produce a cascade of symptoms (palpitations, brain fog, fatigue, shakiness) that mimic POTS flares and trigger mast cell activity.

## Plain-language summary

Chromium is an essential trace mineral that supports how your body responds to insulin and processes carbohydrates. We include it at 200 micrograms - the standard supplement dose with the deepest human safety data - because the EDS/POTS/MCAS triad commonly comes with overlapping reactive hypoglycemia. Post-meal blood sugar dips can produce a cascade of symptoms (palpitations, brain fog, fatigue, shakiness) that mimic POTS flares and trigger mast cell activity. Supporting glucose regulation removes one common confounding variable. We use chromium picolinate - the most-studied form with the cleanest absorption profile of any practical chromium supplement.

## Mechanism

Chromium is an essential trace mineral that supports how your body responds to insulin and processes carbohydrates. We include it at 200 micrograms - the standard supplement dose with the deepest human safety data - because the EDS/POTS/MCAS triad commonly comes with overlapping reactive hypoglycemia. Post-meal blood sugar dips can produce a cascade of symptoms (palpitations, brain fog, fatigue, shakiness) that mimic POTS flares and trigger mast cell activity. Supporting glucose regulation removes one common confounding variable. We use chromium picolinate - the most-studied form with the cleanest absorption profile of any practical chromium supplement.

## Condition-specific notes

### MCAS (Mast Cell Activation Syndrome)

Chromium doesn't directly engage mast cell biology - it's a trace mineral, not a mast cell stabilizer. The MCAS-relevant story is indirect: reactive hypoglycemia and post-meal blood sugar swings are common triggers for mast cell activation in sensitive patients. The adrenaline spike that comes with a sugar crash can drive mast cell degranulation, and the inflammatory aftermath of irregular glucose handling can amplify baseline mast cell reactivity. Supporting glucose regulation removes one upstream trigger without targeting mast cells directly. It's foundational background work that complements the dedicated mast cell stabilizers elsewhere in the formulation.

### hEDS (hypermobile Ehlers-Danlos Syndrome)

Chromium doesn't have a direct connective tissue mechanism - it's not a collagen ingredient. The hEDS-relevant case is indirect: many hEDS patients live with chronic fatigue and post-exertional crashes that can be amplified by reactive hypoglycemia. Steady glucose handling means more even energy through the day and fewer of the metabolic dips that compound the structural fatigue of hEDS. Chromium is part of the trace mineral foundation - modest, reliable, and addressing a common comorbid issue rather than the core pathology. The targeted ECM-protective work happens elsewhere in the formulation.

### POTS (Postural Orthostatic Tachycardia Syndrome)

This is where chromium earns its inclusion. Many POTS patients have reactive hypoglycemia - a post-meal blood sugar dip that produces palpitations, sweating, brain fog, and shakiness that's easily mistaken for POTS flares (or that genuinely triggers POTS-like autonomic responses). Studies in glucose-tolerance-impaired patients consistently show chromium supplementation supports more stable post-meal blood sugar. Steadier glucose means fewer of the adrenaline-driven autonomic surges that come with a sugar crash. For POTS patients who notice clear post-meal symptom patterns, addressing the glucose layer can take meaningful pressure off the autonomic system.

## Why this form

**Selected form:** Chromium picolinate, USP grade, 200 mcg AM

We use chromium picolinate at 200 micrograms - the form and dose with the deepest human safety record. Chromium has terrible absorption in most forms (often under 1%); picolinic acid is a natural chelator that lifts absorption to around 2-3%, the highest of any practical supplement form. The 200 mcg dose sits in the well-studied range (50-400 mcg in trials), avoiding the cumulative concerns around the much higher doses (1,000+ mcg) used in some diabetes trials. This is a multivitamin-completion ingredient: modest dose, strong safety, real trace mineral coverage at negligible bulk weight.

## Evidence summary

### Glucose Handling and Insulin Response

Meta-analytic evidence in glucose-tolerance-impaired and type 2 diabetic populations consistently shows chromium supplementation supports more stable post-meal blood sugar and lower fasting glucose. Reactive hypoglycemia is the indirect mechanism that connects chromium to the triad: post-meal sugar dips drive adrenaline-mediated autonomic surges that mimic or amplify POTS flares.

- [1] **Suksomboon N et al., "Systematic review and meta-analysis of the efficacy and safety of chromium supplementation in diabetes".** Design: Systematic review + meta-analysis of 25 RCTs in T2DM. Finding: Chromium supplementation significantly reduced fasting plasma glucose (mean -1.0 mmol/L) and HbA1c (-0.55%) vs placebo; effect dose-dependent and most consistent with the picolinate form. PMID: 24635480.
- [2] **Huang H et al., "Chromium supplementation for adjuvant treatment of type 2 diabetes mellitus: results from a pooled analysis".** Design: Pooled analysis of RCTs in T2DM, 22 trials. Finding: Significant reductions in fasting glucose and HbA1c with chromium picolinate vs placebo; effect plateaued around 200-400 mcg/day with no added benefit at higher doses. PMID: 28677892.
- [4] **Ghosh D et al., "Role of chromium supplementation in Indians with type 2 diabetes mellitus".** Design: RCT, 50 T2DM patients, 400 mcg/day chromium picolinate vs placebo for 3 months. Finding: Significant improvements in fasting and post-prandial glucose and HbA1c in the chromium arm vs placebo. PMID: 12550067.
- [5] **Havel PJ, "A scientific review: the role of chromium in insulin resistance".** Design: Mechanistic review. Finding: Chromium supports insulin receptor signaling via chromodulin (LMWCr); deficiency or marginal status impairs glucose handling. Mechanistic rationale for supplementation in insulin-resistant phenotypes. PMID: 15208835.

### Cardiovascular and POTS-Relevant Effects

A small RCT in T2DM showed chromium picolinate shortened the QTc interval (an autonomic marker), suggesting parasympathetic-side autonomic effects beyond glucose handling alone. Relevant context for the POTS-overlap reactive-hypoglycemia inclusion rationale.

- [6] **Vrtovec M et al., "Chromium supplementation shortens QTc interval duration in patients with type 2 diabetes mellitus".** Design: Double-blind RCT, 60 T2DM patients, 1000 mcg/day chromium picolinate for 3 months. Finding: Chromium significantly shortened QTc interval vs placebo (consistent with improved autonomic balance); supports chromium's relevance beyond pure glycemic control. PMID: 15990745.

### Long-Term Safety at Supplement Doses

Chromium picolinate at the 200 mcg supplement dose has decades of human use without serious adverse events. Meta-analytic safety review confirms tolerability in T2DM populations and the dose well below the 1,000 mcg Tolerable Upper Intake Level.

- [3] **Georgaki MN et al., "The role of chromium supplementation in human health and disease: a review".** Design: Comprehensive review of chromium efficacy and safety. Finding: Standard supplement doses (200-400 mcg/day picolinate) consistently well-tolerated across long-duration trials; renal concerns limited to extreme chronic dosing in patients with pre-existing kidney disease. PMID: 39541030.

## Safety

**Side effects:** Excellent tolerability at the 200 mcg supplement dose; decades of human use without serious adverse events in trials up to 12 months. Very rare reports of mild GI discomfort. The dose is one-fifth of the Tolerable Upper Intake Level (1,000 mcg), with substantial safety margin.

**Interactions:** Theoretical interaction with diabetes medications (insulin, metformin); if you are on either, mention chromium to your prescriber since improved glucose handling might affect dosing requirements. Chromium picolinate does not engage CYP enzymes meaningfully and has no documented interactions with the standard POTS, MCAS, or hEDS medication stack.

**Excipients to avoid:** Fermentation-derived sources, Artificial colors, Magnesium stearate

**Excipients that are safe:** HPMC capsules, Rice flour, Cellulose

## Frequently asked questions

### Why include chromium in a formulation for hEDS/POTS/MCAS?

Reactive hypoglycemia - a post-meal blood sugar dip - produces symptoms that overlap with POTS and MCAS: palpitations, sweating, shakiness, brain fog, sometimes anxiety. Many people in the triad have it without knowing, and it can amplify autonomic symptoms or trigger mast cell flares. Supporting normal glucose handling is foundational background work that addresses one common confounder. Chromium isn't a hero ingredient; it's part of the trace mineral floor that lets the more targeted ingredients do their work.

### Will chromium interact with my POTS medications?

No documented interactions with the standard POTS medication stack: beta-blockers, midodrine, fludrocortisone, ivabradine. Chromium picolinate doesn't engage the CYP enzymes that drive most drug interactions. Some interaction is theoretically possible with diabetes medications (insulin sensitizers) - if you're on metformin or insulin, mention chromium to your prescriber, since better glucose handling might mean your doses need adjustment. For most POTS patients without diabetes, chromium is a clean addition.

### Is chromium picolinate safe long-term?

Yes. Chromium picolinate has decades of human use at the 200 mcg supplement dose without serious adverse events in trials running up to a year. Older case reports raised concerns at very high doses (1,000+ mcg over months) in people with kidney disease, but those don't apply to standard supplement levels. The biggest risk with chromium is buying poorly-made products - we source pharmaceutical-grade picolinate with full Certificate of Analysis on every batch.

### What about chromium picolinate vs other chromium forms?

Picolinate is the most-studied form with the best absorption - around 2-3% bioavailability, which is high for chromium (most forms are under 1%). Chromium chloride and chromium polynicotinate are alternatives, but neither has the same depth of human trial data. For an essential trace mineral where the goal is reliable repletion at a modest dose, picolinate is the standard choice. It's the form used in nearly every supplement study showing glucose-handling benefits.

## References

[1] Suksomboon N et al.. (2014). Systematic review and meta-analysis of the efficacy and safety of chromium supplementation in diabetes. PMID: 24635480. https://pubmed.ncbi.nlm.nih.gov/24635480/
[2] Huang H et al.. (2017). Chromium supplementation for adjuvant treatment of type 2 diabetes mellitus: results from a pooled analysis. PMID: 28677892. https://pubmed.ncbi.nlm.nih.gov/28677892/
[3] Georgaki MN et al.. (2024). The role of chromium supplementation in human health and disease: a review. PMID: 39541030. https://pubmed.ncbi.nlm.nih.gov/39541030/
[4] Ghosh D et al.. (2002). Role of chromium supplementation in Indians with type 2 diabetes mellitus. PMID: 12550067. https://pubmed.ncbi.nlm.nih.gov/12550067/
[5] Havel PJ. (2004). A scientific review: the role of chromium in insulin resistance. PMID: 15208835. https://pubmed.ncbi.nlm.nih.gov/15208835/
[6] Vrtovec M et al.. (2005). Chromium supplementation shortens QTc interval duration in patients with type 2 diabetes mellitus. PMID: 15990745. https://pubmed.ncbi.nlm.nih.gov/15990745/